Luca Benatti is Chief Executive Officer and member of the Board of Tes Pharma. He is an entrepreneur with more than 30 years of experience in Pharma and Biotech. He was the CEO of EryDel since 2012, recently acquired by Quince Therapeutics. and the Co-founder and CEO of Newron Pharmaceuticals. Under his guidance, Newron developed a pipeline of innovative therapies including Xadago, approved worldwide for the treatment of Parkinson's disease. Since 2014 he was also Board member of Intercept Pharmaceuticals sold to Alfasigma in 2023 He is an independent Board member at Newron Pharmaceuticals (NWRN), Cas Revolution, EV Biosolutions and Founder & Chairman of the Italian Angels for Biotech. He has authored several scientific publications and holds numerous patents.

Federica is Managing Partner of XGEN Venture and currently serves on the boards of EpilepsyGTx, Protembis, Aavantgarde and InnovHeart. She co-founded XGEN in 2021 leveraging extensive expertise in life sciences and venture capital. Before XGEN, Federica was Investment Director at Genextra from 2006, where she continues to contribute as a board member and co-investor in its portfolio companies. Her previous roles include board positions at Erydel and Kuste Biopharma, as well as operational roles such as COO of Congenia. Federica began her career in academia as a postdoctoral fellow at the Medical Research Council (MRC) in Cambridge, UK, focusing on the structural biology of mitochondrial proteins. She is actively involved in the life sciences community as a co-founder of Italian Angels for Biotech (IAB) and a former board member of Assobiotec. Federica holds an MBA from Columbia University, a PhD specializing in protein crystallography, and a master’s degree in biochemistry (summa cum laude) from the University of La Sapienza in Rome.

Paolo is Managing Partner at XGEN Venture and is board member for TES Pharma, NanoPhoria and Genespire and board observer for Nouscom and iOnctura. Before co-founding XGEN in 2021, he was in Genextra since its inception in 2004, serving as CEO up to 2022. Paolo is also board member and co-investor of a number of Genextra companies including InnovHeart and iOncologi Therapeutics. Previous companies include EryDel and Intercept Pharmaceutical where he served also as Chairman until the Alfasigma acquisition in 2023. Prior to Genextra, he gained several start-up experiences, including Fastweb (2000-2004), and as investment banker in London (1997-2000). Paolo is co-founder of Italian Angels for Biotech (IAB). He holds a cum laude degree in B.A. & Finance from Bocconi University.

Paola has been a manager and an entrepreneur, and now she is also a business angel and keep going as a mom of a 9 years old daughter. Paola has spent 11 years as a talented manager with growing business responsibilities in P&G, both pharma and mass market, then Astrazeneca, UCB and BMS. In 2010 Paola opened her two companies, focusing in the growing area of market access and pricing (3P SOLUTION and MA Provider), and acquiring in 2018 a third company (Argon Healthcare now MAPCOM CONSULTING) to compliment the full areas of service to pharma companies. In 2017, she founded with the University of Piemonte Orientale (UPO) the ATMPFORUM, the first project on ATMP, opened in Italy, and is now ATMPFORUM director. At the end of 2021, she sold the 3 companies (13 millions sales and 70 people), to Pharmalex a global company focused on high level service provider in the lifescience field, and now is serving as MAP Group CEO. Since 2021, Paola is CDA President of Rocket Social, a young company focused on digital marketing to understand and exploit the opportunities of digital health. Paola started also her activity as business angel, as Angel for Women association and now IAB, investing in female companies, mainly in lifescience. She is passionated about business in lifescience, with particular interest on pricing topics, ATMP and all kind of innovation in general, with a positive but challenging approach.

Giovanni is CEO of iDNA Ltd, a consulting firm for drug discovery and early preclinical development, helping start-up for funds raising through access to business investors, venture capital firms and pharmaceutical companies. He is also Honorary Senior Lecturer at University College London (UCL) and Peer Reviewer Expert – European Commission. He was Head of Biology at Intercept Pharmaceuticals (ICPT), a NY-based biotech company, focused on liver diseases from 2006 to 2014. In 2014 was appointed Vice President of E3Bio, an Index Venture portfolio Company. He received the MBA from HULT business school – London

Chiara is Vice-President of the board of Zambon Company S.p.A., holding of the Group, member of the Board of Directors of Zambon S.p.A. and of ZaCh – Zambon Chemicals. She is also member of the Strategic Advisory Board of Zambon and followed, as member of the Board of Directors, from its origins in 2003, ZCube the incubator of Zambon Group. From 1989 to 1999 worked in the Research & Development department of Zambon as in-vivo pharmacology scientist within the Central Nervous System research team, assistant to the development product Project Leader within the cardiovascular area and within the R&D Planning & Control team. Chiara hold a Bachelor degree in chemistry and pharmaceutical technologies and specialization in Pharmacology at the University of Milan. She is also member of the Board of Zoé Foundation, Zambon Open Education.